Mehmet Ugur Mungan

Purpose: To investigate the effect of metformin use on recurrence and progression in nonmuscle invasive bladder cancer patients (NMIBC). Material method: Patients who underwent primary transurethral bladder tumor resection between 2016 and 2020 were screened. Only patients with NMIBC were included in the study. The patients were divided into two groups according to the use of metformin and the groups were compared in terms of recurrence and progression. Results: According to inclusion criteria 176 NIMBC patients were included in the study. Metformin use was detected in 37 patients. The demographic characteristics and follow-up times of the patients were similar between the user and nonuser groups. Recurrence was detected in only 8.1% of the metformin user group. On the other hand, the recurrence rate was 32.4% in the nonuser group. There was no progression in the metformin user group. But in the non-user group progression rate was 8,6%. Conclusion: In our study, we found that recurrence and progression rates were lower in metformin-using patients. Prospective randomized trials are needed to understand the effects of metformin use on bladder cancer.

Comparison of laparoscopic and laparotomic Burch colposuspension in the treatment of stress urinary incontinence - Journal of the Turkish-German Gynecological Association

The aim of the study was to demonstrate the most common genetic alterations and evaluate possible targets involving phosphatidylinositol-3-OH kinase (PIK3)/AKT/mammalian target of rapamycin (mTOR) signaling and DNA damage repair (DDR) pathways for personalized treatment in patients with non-muscle invasive bladder cancer (NMIBC). Alterations of these pathways were observed in 89.5% and 100% of patients, respectively. Among them, BARD1 was more frequently altered in low/intermediate-risk cases, but PARP4 was more frequently affected in intermediate/high-risk patients. The possible target feasibility of BARD1 and PARP4 alterations should be evaluated for personalized treatment using PARP-inhibitors in NMIBC. It is important to detect high tumor mutation burden (TMB) in patients in terms of immunotherapy.

Aim: To evaluate the ex vivo efficacy of chemotherapy, immunotherapy and targeted agents with the oncogram method in patients with bladder cancer and determine the most appropriate personalized tre... Plain language summary Bladder cancer primary cell cultures were shown to be effective for drug sensitivity and also able to be used ex vivo in the process of determining personalized treatment. Th... Tweetable abstract Evaluation of drug responses detected by oncogram can provide important information for pretreatment drug selection when determining individualized treatment. These results show ...

Aim of this study is to compare the effects of partial nephrectomy (PN) and radical nephrectomy (RN) for stage I renal cell carcinoma (RCC) on renal functions in patients with diabetes mellitus (DM) and/or hypertension (HT). Charts of patients who underwent surgery for stage I RCC in our department were retrospectively reviewed and patients with DM and/or HT were enrolled. Preoperative and postoperative estimated glomerular filtration rates (eGFR) were calculated according to the Modification of Diet in Renal Disease (MDRD) formulation for both RN and PN groups. Groups were compared for patient demographics, preoperative eGFR, postoperative eGFR and ΔeGFR [(preoperative eGFR) – (postoperative eGFR)] which reflects the renal functional loss. There were 85 patients in the RN and 33 patients in the PN groups. Demographic data were similar but the patients in the PN group had smaller tumor size compared to RN group (32.2 ± 11.8 mm vs 47.1 ± 15.2 mm, p < 0.001). Preoperative eGFR did not differ between groups (75 ± 28.4 mL/min/1.73 m² vs 75.5 ± 23.8 mL/min/1.73 m² in RN and PN groups, p = 0.929). However, there were significant differences between groups in terms of postoperative eGFR (57.5 ± 21.7 mL/min/1.73 m² vs 74 ± 27.5 mL/min/1.73 m² in RN and PN groups, p < 0.001) and ΔeGFR (17.5 ± 4.2 mL/min/1.73 m² vs 1.5 ± 0.4 mL/min/1.73 m² in RN and PN groups, p < 0.001). Our findings favor the use of PN over RN for stage I RCC whenever feasible in patients with predisposing systemic diseases for chronic kidney disease for better preservation of renal functions.